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Abstract
While widespread genome sequencing ushers in a new era of preventive medicine, the tools for predictive genomics are still
lacking. Time and resource limitations mean that human diseases remain uncharacterized because of an inability to predict
clinically relevant genetic variants. A strategy of targeting highly conserved protein regions is used commonly in functional
studies. However, this benefit is lost for rare diseases where the attributable genes are mostly conserved. An immunological
disorder exemplifying this challenge occurs through damaging mutations in RAG1 and RAG2which presents at an early age with
a distinct phenotype of life-threatening immunodeficiency or autoimmunity. Many tools exist for variant pathogenicity predic-
tion, but these cannot account for the probability of variant occurrence. Here, we present a method that predicts the likelihood of
mutation for every amino acid residue in the RAG1 and RAG2 proteins. Population genetics data from approximately 146,000
individuals was used for rare variant analysis. Forty-four known pathogenic variants reported in patients and recombination
activity measurements from 110 RAG1/2 mutants were used to validate calculated scores. Probabilities were compared with 98
currently known human cases of disease. A genome sequence dataset of 558 patients who have primary immunodeficiency but
that are negative for RAG deficiency were also used as validation controls. We compared the difference between mutation
likelihood and pathogenicity prediction. Our method builds a map of most probable mutations allowing pre-emptive functional
analysis. This method may be applied to other diseases with hopes of improving preparedness for clinical diagnosis.
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Introduction
Costs associated with genomic investigations continue to re-
duce [1], while the richness of data generated increases.
Globally, the adoption of wide-scale genome sequencing im-
plies that all newborn infants may receive screening for path-
ogenic genetic variants in an asymptomatic stage, pre-
emptively [2]. The one dimensionality of individual genomes
is now being expanded by the possibility of massive parallel
sequencing for somatic variant analysis and by single-cell or
lineage-specific genotyping, culminating in a genotype spec-
trum. In whole blood, virtually every nucleotide position may
be mutated across 105 cells [3]. Mapping one’s genotype
across multiple cell types and at several periods during a per-
son’s life may soon be feasible [4]. Such genotype snapshots
might allow for prediction and tracking of somatic, epigenetic,
and transcriptomic profiling.
The predictive value of genomic screening highly depends
on the computation tools used for data analysis and its corre-
lation with functional assays or prior clinical experience.
Interpretation of that data is especially challenging for rare
human genetic disorders; candidate disease-causing variants
that are predicted as pathogenic often require complex func-
tional investigations to confirm their significance. There is a
need for predictive genomic modelling with aims to provide
reliable guidance for therapeutic intervention for patients har-
boring genetic defects for life-threatening disease before the
illness becomes clinically significant.
The study of predictive genomics is exemplified by con-
sideration of gene essentiality, accomplished by observing
intolerance to loss-of-function variants. Several gene essen-
tiality scoring methods are available for both the coding and
non-coding genome [5]. Approximately 3000 human genes
cannot tolerate the loss of one allele [5]. The greatest hurdle
in monogenic disease is the interpretation of variants of un-
known significance while functional validation is a major
time and cost investment for laboratories investigating rare
disease.
Severe, life-threatening immune diseases are caused by ge-
netic variations in almost 300 genes [6, 7]; however, only a
small percentage of disease-causing variants have been char-
acterized using functional studies. Several robust tools are in
common usage for predicting variant pathogenicity.
Compared with methods for pathogenicity prediction, a void
remains for predicting mutation probability, essential for effi-
cient pre-emptive validation. Our investigation aims to apply
predictive genomics as a tool to identify genetic variants that
are most likely to be seen in patient cohorts.
We present the first application of our novel approach of
predictive genomics using Recombination activating gene 1
(RAG1) and RAG2 deficiency as a model for a rare primary
immunodeficiency (PID) caused by autosomal recessive var-
iants. RAG1 and RAG2 encode lymphoid-specific proteins
that are essential for V(D)J recombination. This genetic re-
combination mechanism is essential for a robust immune re-
sponse by diversification of the T and B cell repertoire in the
thymus and bone marrow, respectively [8, 9]. Deficiency of
RAG1 [10] and RAG2 [11] in mice causes inhibition of B and
T cell development. Schwarz et al. [12] formed the first pub-
lication reporting that RAGmutations in humans cause severe
combined immunodeficiency (SCID), and deficiency in pe-
ripheral B and T cells. Patient studies identified a form of
immune dysregulation known as Omenn syndrome [13, 14].
The patient phenotype includes multi-organ infiltration with
oligoclonal, activated T cells. The first reported cases of
Omenn syndrome identified infants with hypomorphic RAG
variants which retained partial recombination activity [15].
RAG deficiency can be measured by in vitro quantification
of recombination activity [16–18]. Hypomorphic RAG1 and
RAG2 mutations, responsible for residual V(D)J recombina-
tion activity (on average 5–30%), result in a distinct pheno-
type of combined immunodeficiency with granuloma and/or
autoimmunity (CID-G/A) [2, 19, 20].
Human RAG deficiency has traditionally been identified
at very early ages due to the rapid drop of maternally ac-
quired antibody in the first six months of life. A loss of
adequate lymphocyte development quickly results in com-
promised immune responses. More recently, we have found
that RAG deficiency is also found for some adults living with
PID [16].
RAG1 and RAG2 are highly conserved genes, but disease
is only reported with autosomal recessive inheritance. Only
44% of amino acids in RAG1 and RAG2 are reported as
mutated on GnomAD, and functional validation of candidate
variants is difficult [21]. Pre-emptive selection of residues
for functional validation is a major challenge; a selection
based on low allele frequency alone is infeasible since the
majority of each gene is highly conserved. A shortened time
between genetic analysis and diagnosis means that treat-
ments may be delivered earlier. RAG deficiency may present
with diverse phenotypes, and treatment strategies vary. With
such tools, early intervention may be prompted. Some pa-
tients could benefit from hematopoietic stem cell transplant
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[22] when necessary, while others may be provided
mechanism-based treatment [23]. Here, we provide a new
method for predictive scoring that was validated against
groups of functional assay values, human disease cases,
and population genetics data. We present the list of variants
most likely seen as future determinants of RAG deficiency,
meriting functional investigation.
Methods
Population Genetics and Data Sources
GnomAD (version r2.0.2) [21] was queried for the canonical
transcripts of RAG1 and RAG2 from population genetics data
of approximately 146,000 individuals; ENST00000299440
(RAG1) 1586 variants, GRCh37 11:36532259-36614706
and ENST00000311485 (RAG2) 831 variants, GRCh37
11:36597124 - 36619829. Data was filtered to contain the
variant effect identifiers: frameshift, inframe deletion,
inframe insertion, missense, stop lost, or stop gained.
Reference transcripts were sourced from Ensembl in the
FASTA format amino acid sequence for transcript RAG1-
201 ENST00000299440.5 [HGNC:9831] and transcript
RAG2-201 ENST00000311485.7 [HGNC:9832]. These se-
quences were converted to their three-letter code format
using One to Three from the Sequence Manipulation Suite
(SMS2) [24]. Combined Annotation Dependent Depletion
(CADD) scores were sourced from https://cadd.gs.
washington.edu/download (Nov 2018) and are reported by
Kircher et al. [25]. The dataset used was “All possible
SNVs” from whole-genome data, from which we extracted
the data for coding regions of RAG1 and RAG2. We used the
Human Gene Mutation Database (HGMD) from the Institute
of Medical Genetics in Cardiff as a pre-defined source of
known RAG deficiency cases http://www.hgmd.cf.ac.uk/
ac/index.php [26] (Feb 2019, free access version to NM_
000448.2). Data was formatted into CSV and imported into
R for combined analysis with PHRED-scaled CADD scores
and the main data frame. The crystal structure render of
DNA-bound RAG complex was produced with data from
RCSB Protein Data Bank (3jbw.pdb) [27]. Structures were
visualized using the software VMD from the Theoretical and
Computational Biophysics Group [28], imaged with
Tachyon rendering [29], and color mapped using our scoring
method.
Data Processing
The population genetics input dataset used GnomAD variant
allele frequencies and reference sequences processed as CSV
files and cleaned and sorted to contain only amino acid codes,
residue numbers, alternate residues, alternate allele
frequencies, and a score of 0 or 1 to indicate presence or
absence of variants where 1 represented none reported. An
annotation column was also provided to label where multiple
alternate variants existed. Statistics and calculation steps are
listed in order in Supplemental Tables E3–E8.
The percentage of conserved residues was calculated
(55.99% of amino acids contained no reported variants in
RAG1, 55.98% in RAG2 (Table E4)). Basic protein statistics
were generated using canonical reference transcript sequences
of RAG1 and RAG2 with the SMS2 tool Protein Stats [24].
The resulting pattern percentage value was converted to a
frequency (decimal 0–1) based on the number of residues
per protein to generate the residue frequency (Rf). The Rf
values were found for both proteins as shown in Table E5
and summarized in Table E6.
The count of variants per residue was found for both pro-
teins, and the mutation rates (Mr) per residue were calculated
as shown in Table E7.Mr was found by counting the number
of mutations per residue in a window, sized to contain each
protein individually. For genome-wide application, the win-
dow size may be increased or decreased. In this case, the
window consisted of only the coding regions. TheMr values
were then converted to frequencies based on the number of
residues per protein. Separate, and overlapping, windows
could also be used based on genome phase data and regions
of linkage disequilibrium to account for non-random associ-
ation of alleles at different loci; this might be particularly
important for disorders with multiple genetic determinants.
The Mr and Rf multiply to give the raw mutation rate res-
idue frequency (MRF) value (Table E8). This value is also
shown in Tables 1 and E1. Our investigation used a Boolean
scoreC to account for the presence or absence of a mutation in
the general population, 0 for any variant existing in the popu-
lation and 1 for conserved residues. C ×Mr × Rf, in our case,
produced the MRF score for conserved residues. Figure 1a
illustrates the raw MRF as a histogram and the MRF, after
applying C, as a heatmap.
An important consideration for future application is
whether to use this Boolean score or instead use a discrete
variable which accounts for the true allele frequency in the
general population. In the clinical setting, the likelihood of
de novo mutations and inherited mutations have different
impacts when considering recessive and dominant diseases.
A patient is more likely to inherit a variant that exists even at
a very low frequency than to acquire a random de novo
mutation. Therefore, a value representing an allele frequency
may be used to replace C in many investigations, particularly
when considering variants that exist at low rates. PRHED-
scaled CADD score data consisted of nucleotide level
values. For comparison with MRF, the median CADD scores
were averaged per codon as demonstrated in Supplemental
text. A summary of data processing and analysis is illustrated
in Fig. E1.
690 J Clin Immunol (2019) 39:688–701
Raw Data Availability and Analysis Script
The Supplemental “Raw_data_R_analysis_for_figures” contains
all raw data and analysismethods used to produce figures (except
illustrations in Figs. 1 and 6). “data_analysis.R” is anR script that
contains the methods used to produce figures. Each of the input
data CSV files is explained on the first usage within the analysis
script. Running “data_analysis.R” from within the same directo-
ry as the associated input data CSV files will replicate analysis.
Table 1 MRF likelihood scores for variants functionally assayed to date
[16–18]. Increased MRF score indicates a higher likelihood of occurrence.
Recombination activity is shown as a percentage of wild type (% SEM).
Residues with multiple mutations are shown with both alternative variants
and values. MRFmax = 0.043 and MRFmin = 0.004. The full table of all
protein positions can be found in Supplemental Table E1
RAG1
MRF Residue Assayed Recombination activity (%)
0.03 56 I56T 3.5 ± 0.2
0.03 86 K86VfsX33 2.7 ± 0.3
0.014 99 G99S 113.2 ± 3.7
0.012 106 N106K 80.4 ± 16.4
0.043 108 R108X 1.8 ± 0.3
0.043 142 R142X 9.0 ± 4.0
0.032 174 E174SfsX27 0.5 ± 0.2
0.027 246 A246TfsX17 0.8 ± 0.1
0.012 248 Q248X 1.2 ± 0.2
0.026 249 H249R 112.2 ± 3.5
0.043 314 R314W 24.3 ± 5.2
0.012 328 C328Y 16.0 ± 2.9
0.03 383 K383RfsX7 0.1 ± 0.0
0.013 386 F386CfsX4<a0> 0.2 ± 0.1
0.03 391 K391E 6.5 ± 1.6
0.043 394 R394Q 0.1 ± 0–0.1
0.043 396 R396C 0.4–0.6 ± 0–0.1
0.041 401 S401P 0.0 ± 0.0
0.02 403 T403P 0.0 ± 0.0
0.043 404 R404Q 1.2 ± 0.1
0.043 410 R410Q 0.0 ± 0.0
0.025 411 L411P 0.0 ± 0.0
0.022 429 D429G 0.1 ± 0.0
0.028 433 V433 M 0.2 ± 0.0
0.019 435 M435 V 23.6 ± 4.8
0.027 444 A444V 1.4 ± 0.2
0.043 449 R449K 92.1 ± 3.6
0.025 454 L454Q 5.4 ± 0.7
0.019 458 M458SfsX34 0.0 ± 0.0
0.027 472 A472V 0.4 ± 0.0
0.043 474 R474C 125.4 ± 2.6
0.028 475 V475AfsX17 0.1 ± 0.0
0.025 506 L506F 1.0 ± 0.1
0.043 507 R507W 15.9 ± 0.8
0.014 516 G516A 40.2 ± 1.3
0.005 522 W522C 41.6 ± 1.9
0.022 539 D539V 3.2 ± 0.2
0.025 541 L541CfsX30 1.2 ± 0.9
0.043 559 R559S 1.0 ± 0.4
0.043 561 R561H 2.0 ± 0.6
0.041 601 S601P 0.0 ± 0.0
0.026 612 H612R 121.6 ± 0.9
0.043 624 R624H 0.0 ± 0.4
0.041 626 S626X 0.0 ± 0.0
0.041 651 S651P 0.5 ± 0.5
0.043 699 R699Q,W 45.9 ± 1.5, 19.3 ± 1.8
0.032 722 E722K 0.0 ± 0.2
0.012 730 C730F 0.0 ± 0.0
0.025 732 L732P 0.0 ± 0.0
0.043 737 R737H 0.2 ± 0.0
0.043 759 R759C 17.2 ± 3.3
0.043 764 R764P 0.0 ± 0.0
0.008 768 Y768X 0.0 ± 0.0
0.032 770 E770K 21.0 ± 0.4
0.043 778 R778Q,W 8.6 ± 1.0, 4.6 ± 0.6
0.028 786 P786L 0.0 ± 0.1
0.03 820 K820R 117.9 ± 6.3
0.025 836 L836 V 75.0 ± 1.3
0.043 841 R841Q,W 0.0 ± 0.0, 10.0 ± 0.5
0.027 868 A868V 100.0 ± 5.0
Table 1 (continued)
0.005 896 W896R 0.9 ± 0.1
0.008 912 Y912C 6.9 ± 0.4
0.005 959 W959X 0.0 ± 0.0
0.032 965 E965X 0.0 ± 0.0
0.043 973 R973C 0.0 ± 0.2
0.013 974 F974 L 56.5 ± 0.8
0.043 975 R975W,Q 57.9 ± 1.6, 53.5 ± 3.6
0.012 981 Q981P 7.2 ± 0.1
0.03 983 K983NfsX9 0.1 ± 0.0
0.03 992 K992E 9.1 ± 1.2
0.03 1006 M1006 V 105.6 ± 6.8
RAG2
0.013 1 M1T 65.3 ± 2.2
0.006 16 Q16X 1.7 ± 0.4
0.038 35 G35A,V 22.1 ± 3.1, 0.4 ± 0.3
0.023 39 R39G 0.2 ± 0.1
0.011 41 C41W 0.2 ± 0.4
0.017 62 F62 L 19.6 ± 3
0.028 65 D65Y 6.8 ± 1.2
0.023 73 R73H 12.4 ± 1.4
0.034 77 T77 N 42.6 ± 2.7
0.038 95 G95R 0.3 ± 0.2
0.013 110 M110 L 74.6 ± 1.8
0.017 127 K127X 0.1 ± 0
0.038 157 G157 V 0.4 ± 0.2
0.03 160 S160 L 5.8 ± 0.6
0.023 180 P180H 31.1 ± 0.5
0.019 195 Y195D 2 ± 0.3
0.034 215 T215I 67.2 ± 1
0.023 229 R229Q,W 8.9 ± 1, 10.5 ± 0.5
0.023 253 P253R 95.4 ± 2.3
0.006 278 Q278X 0.1 ± 0.1
0.013 285 M285R 24.7 ± 0.8
0.004 307 W307X 0.2 ± 0.2
0.017 386 F386 L 109.1 ± 5
0.025 407 E407X 2.9 ± 0.4
0.004 416 W416 L 1.4 ± 0.2
0.025 437 E437K 0.9 ± 0.2
0.017 440 K440 N 26.7 ± 2.4
0.013 443 M443I 0.4 ± 0.2
0.027 444 I444M 2.7 ± 0.3
0.011 446 C446W 2.9 ± 0.1
0.038 451 G451A 66.3 ± 4.8
0.004 453 W453R 0.6 ± 0.1
0.017 456 A456T 16 ± 2.9
0.013 459 M459 L 30.8 ± 0.6
0.034 474 N474S 97.5 ± 5.9
0.011 478 C478Y 0.2 ± 0.1
0.025 480 E480X 2.8 ± 0.6
0.017 481 H481P 23.8 ± 3.9
0.013 502 M502 V 99.6 ± 3.4
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Data Visualization
For our visualization of MRF scores, small clusters of high
MRF values were more appealing than individual highly con-
served residues. Therefore, we applied a 1% average filter
where values were averaged over a sliding window of N num-
ber of residues (10 in the case of RAG1, 6 in the case of
RAG2). For a clear distinction of MRF clusters, a cutoff
threshold was applied at the 75th percentile (e.g., 0.0168 in
RAG1) as shown in heatmaps in Figs. 1c and 6. The gene
heatmaps for coding regions in RAG1 and RAG2 (Fig. 1)
were populated with (i) Boolean C score from population
genetics data, (ii) rawMRF scores, and (iii) MRF clusters with
1% average and cutoff threshold. GraphPad Prism was used
for heatmaps. The data used for heatmaps is available in
Table E1 and in the supplemental R source to allow for alter-
native visualizations. An example of alternative output for
non-R users is shown in Fig. E2. Adobe Illustrator and
Photoshop were used for protein domain illustrations in
Fig. 1d. Data and analysis is summarized in Fig. E1.
Validation of MRF Against Functional Data
The recombination activity of RAG1 and RAG2 was previ-
ously measured on known or candidate pathogenic variants
[16–18]. Briefly, the pathogenicity of variants in RAG1 and
RAG2wasmeasured functionally in vitro by either expression
of RAG1 and RAG2 in combination with a recombination
substrate plasmid containing recombination signal sequence
(RSS) sites which are targeted by RAG complex during nor-
mal V(D)J recombination, or Abelson virus-transformed
Rag2−/− pro-B cells with an RSS-flanked inverted GFP cas-
sette. Recombination events were assessed by quantitative
real-time PCR using comparative CT or expression of GFP
evaluated by flow cytometry, respectively. The inverse score
of recombination activity (0–100%) was used to quantify
pathogenicity of variants in our study. Comparison between
known pathogenicity scores and MRF was done by scaling
MRF scores from 0 to 100% (100% being the highest proba-
bility of occurring as damaging).
Results
RAG1 and RAG2 Conservation and Mutation Rate
Residue Frequency
Variant probability prediction is dependent on population
genetics data. Our study queried GnomAD [21] to identify
conserved residues using a Boolean score C of 0 (present in
population) or 1 (conserved). The gene-specific mutation
rate Mr of each residue was calculated from variant allele
Fig. 1 RAG1 (red, left) and RAG2 (blue, right) conservation and
mutation rate residue frequency. a Gene conservation score, non-
conserved 0 and conserved 1. The color indicates no known mutations
in humans. b Histogram, raw MRF score; Heatmap, MRF prediction for
conserved residues, graded 0 to 0.05 (scale of increasing mutation
likelihood with human disease). c Colored bars indicate most likely clin-
ically relevant variant clusters. MRF score averaged with 1% intervals for
each gene and cutoff below the 75th percentile, graded 0 to 0.03 (noise
reduction method). d Gene structure with functional domains. Full list of
residues and scores available in Table E1.
692 J Clin Immunol (2019) 39:688–701
frequencies. The gene-specific residue frequency Rf repre-
sented the frequency of a residue occurring per gene, ac-
quired by converting gene residue percentage (from the
SMS2 tool Protein Stats) to a frequency (decimal 0–1)
[24]. Together, the values were used to calculate the most
probable disease-causing variants which have not yet been
identified in patients. We termed the resulting score a mu-
tation rate residue frequency, where MRF = C × Mr × Rf.
This score represents the likelihood that a clinically relevant
mutation will occur.
Figure 1 presents the most probable unidentified
disease-causing variants in RAG1/2. Variants with a
low MRF may still be damaging, but resources for
functional validation are best spent on gene regions with
high MRF. Clusters of conserved residues are shown in
Fig. 1a and are generally considered important for pro-
tein structure or function. However, these clusters do
not predict the likelihood of mutation. Raw MRF scores
are presented in Fig. 1b. Histograms illustrate the MRF
without Boolean scoring applied and Fig. 1c provides a
clearer illustration of top MRF score clusters. For visu-
alization, a noise reduction method was applied; a slid-
ing window was used to find the average MRF per 1%
interval of each gene. The resulting scores displayed in
Fig. 1c contain a cutoff threshold to highlight the top-
scoring residues (using the 75th percentile). Variant sites
most likely to present in disease cases are identified by
high MRF scoring. This model may be expanded by the
addition of phenotypic or epigenetic data (Supplemental;
Bayesian probability).
Table E1 provides all MRF scores for both proteins. Raw
data used for calculations and the list of validated residues
of RAG1 and RAG2 are available in Tables E3–E8. Table 1
shows the MRF mutation likelihood score for mutations
that have also been reported as tested for recombination
activity in functional assays. The likelihood of mutation
does not correlate with pathogenicity; Figs. 3 and E3 show
that most mutations tested had severe loss of protein func-
tion, while the likelihood of each mutation occurring in
humans varied significantly. Analysis-ready files are also
available in Supplemental data along with the associated
R source file to allow for alternative visualizations as
shown in Fig. E2.
MRF Scores Select for Confirmed Variants in Human
Disease
We have applied MRF scores to known damaging mutations
from other extensive reports in cases of human disease [12,
15, 17, 19, 20, 30–53] (originally compiled by Notarangelo
et al. [54]). This dataset compares a total of 44 variants. We
expected that functionally damaging variants (resulting in low
recombination activity in vitro) that have the highest
probability of occurrence would be identified with high
MRF scores. MRF prediction correctly identified clinically
relevant mutations in RAG1 and RAG2 (Fig. 2a). Variants
reported on GnomAD which are clinically found to cause
disease had significantly higher MRF scores than variants
which have not been reported to cause disease. We observed
that rare and likely mutations provided high scores while rare
but unlikely or common variants had low scores (Fig. 2b).
Allele frequency is generally the single most important
filtering method for rare disease in whole-genome (and ex-
ome) sequencing experiments. Variants under pressure from
purifying selection are more likely to cause disease than com-
mon variants. However, most RAG mutations are rare.
Therefore, allele frequencies of rare variants reported on
GnomAD cannot differentially predict the likelihood of caus-
ing disease (Fig. 2b). As such, we found no significant differ-
ence between known damaging variants and those that have
not yet been reported as disease causing. The comparison
between Fig. 2a and b illustrates the reasoning for the design
of our method.
Many non-clinically reported rare variants may cause dis-
ease; the MRF score identifies the top clinically relevant can-
didates. Based on the frequency of protein-truncating variants
in the general population, RAG1 and RAG2 are considered to
be tolerant to the loss of one allele, as indicated by their low
probability of being loss-of-function intolerant (pLI) scores of
0.00 and 0.01, respectively [21]. This is particularly important
for recessive diseases such as RAG deficiency where most
new missense variants will be of unknown significance until
functionally validated.
Top Candidate Variants Require Validation
Functionally, characterizing protein activity is both costly and
time consuming. RAG1 and RAG2 have now been investigat-
ed by multiple functional assays for at least 110 coding vari-
ants [16–18]. In each case, researchers selected variants in
RAG1 and RAG2 that were potentially damaging or were iden-
tified from PID patients as the most probable genetic determi-
nant of disease. Functional assays for RAG deficiency in those
cases, and generally, measured a loss of recombination activ-
ity as a percentage of wild-type function (0–100%).
Pre-emptively, performing functional variant studies
benefits those who will be identified with the same vari-
ants in the future, before the onset of disease complica-
tions. While more than 100 variants have been assayed
in vitro, we calculated that only one-quarter of them are
most probable candidates for clinical presentation.
Figure 3 illustrates that while functional work targeted
“handpicked” variants that were ultimately confirmed as
damaging, many of them may be unlikely to arise based on
population genetics data. Figure 3 presents, in increasing
order, the number of potential variants based on the
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likelihood of presentation and stacked by the number of
variants per score category. Variants that have been mea-
sured for their loss of protein activity are colored by se-
verity. Potential variants that remain untested are colored
in grey. Only 21 of the top 66 most probable clinically
relevant variants have been assayed in RAG1.
Supplemental Fig. E3 further illustrates the individual
variants which have been tested functionally (the colored
recombination activity subset of Fig. 3). We compared
predicted MRF scores to assay measurements for 71
RAG1 and 39 RAG2 mutants. Most mutations tested
showed severe loss of protein function (bottom panel of
Supplemental Fig. E3), while the likelihood of each mu-
tation occurring in humans varied significantly (top
panels).
If MRF scoring was used in the same cases pre-
emptively, the loss of investment would be minimal; only
8 variants out of 71 mutants tested had an above-average
MRF score while being measured as functionally benign (a
rate of 11.27%). RAG2 had only 3 out of 39 variants
(7.69%) with an above-average MRF score while function-
ally benign. For the expended resources, approximately
30% more top candidates would have been tested in place
of unlikely and functionally non-damaging mutations.
However, the true measurement of accuracy is limited in
that very few of the most likely clinically relevant variants
predicted by MRF scoring have been tested to date.
False Positives in Transib Domains Do Not Negatively
Impact Prediction
Adaptive immunity is considered to have evolved through
jawed vertebrates after integration of the RAG transposon into
an ancestral antigen receptor gene [55, 56]. The Transib trans-
poson is a 600 amino acid core region of RAG1 that targets
RSS-like sequences in many invertebrates. A linked RAG1/
RAG2 was shown in the lower dueterostome (sea urchin),
indicating an earlier common ancestor than the invertebrate
[57], and more recently, a recombinatorially active RAG
transposon (ProtoRAG) was found in the lower chordate am-
phioxus (or lancelet), the most basal extant chordate and a
“living fossil of RAG” [58].
A set of conserved motifs in core RAG1 are shared with the
Transib transposase, including the critical DDE residue cata-
lytic triad (residues 603, 711, and 965) [59]. Ten RAG1 core
motifs are conserved amongst a set of diverse species includ-
ing human [59]. This evolutionarily conserved region is con-
sidered as most important to protein function. Therefore, we
chose this region to determine if MRF scoring would have a
negative impact if mutations were falsely predicted as clini-
cally important. To assess the influence of a false-positive
effect on prediction, the MRF scores for conserved residues
in this group were compared with GnomAD allele frequen-
cies. Figure 4a plots the MRF (without omitting the Boolean
component C = 0) for conserved Transib motif residues, non-
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conserved Transib motif residues, and non-Transib residues.
Figure 4b shows the percentage of these which were reported
as mutated on GnomAD. By accounting for unreported vari-
ants by applyingC > 0, the resulting effect on incorrectly scor-
ing MRF in the conserved Transib motifs remained neutral.
MRF Predicts RAG Deficiency Amongst PID Patients
Harboring Rare Variants
We have previously measured the recombination activity of
RAG1 and RAG2 disease-causing variants in several patients
[16]. We have compiled our own and other functional assay
data from Lee et al. [17] and Tirosh et al. [18] to produce a
panel of recombination activity measurements for coding var-
iants in both RAG1 and RAG2. RAG deficiency was mea-
sured as the level of recombination potential produced by the
protein complex. Each method of investigation simulated the
efficiency of wild-type or mutant proteins expressed by pa-
tients for their ability to produce a diverse repertoire of T cell
receptor (TCR) and B cell receptor (BCR) and coding for
immunoglobulins. In functional experiments, mutant proteins
were assayed for their ability to perform recombination on a
substrate which mimics the RSS of TCR and BCR in compar-
ison with wild-type protein complex (as % SEM).
By gathering confirmedRAGdeficiency cases, we compiled
the MRF scores for 43 damaging RAG1 variants in 77 PID
cases and 14 damaging RAG2 variants in 21 PID cases (MRF
scores spanning over 22 categories). To test our method against
a strong control group, we identified coding variants in patients
with PID where RAG deficiency due to coding variants has
been ruled out as the cause of disease. We obtained RAG1/2
variants in 558 PID patients who had their genomes sequenced
as part of the NIHR BioResource - Rare Diseases study [16].
Filtering initially identified 32 variants in 166 people. This set
was trimmed to contain only rare variants; 29 variants over 26
MRF scoring categories from 72 cases of non-RAG-deficient
PID. The scatterplot in Fig. 5 shows that most PID cases had
damaging variants with a high MRF score, while PID cases
carried benign variants in RAG1/2 with lower MRF scores,
i.e., anMRF > 0.04was seen for 31 cases of a damaging variant
and only 2 cases of a non-damaging variant. Linear regression
on this control group produced negative or near-zero slopes for
RAG1 and RAG2, respectively. The same analysis for known
damaging mutations in disease cases had significant prediction
accuracy for RAG1. Analysis of RAG2 was not significant.
However, the sample size to date may be too small to signifi-
cantly measure RAG2 MRF scoring although a positive corre-
lation was inferred in Fig. 5 [60]. R source and raw data can be
found in Supplemental material.
MRF Supplements Pathogenicity Prediction Tools
for Translational Research
CADD scoring [25] is an important bioinformatics tool that
exemplifies pathogenicity prediction. While CADD is a valu-
able scoring method, its purpose is not to predict the
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likelihood of variation. Similarly, MRF scoring is not a mea-
sure of pathogenicity. MRF scoring may be complemented by
tools for scoring variant deleteriousness. We compare MRF to
the PHRED-scaled CADD scores for all possible SNV
positions in RAG1 (Fig. 6) illustrating that pathogenicity pre-
diction cannot account for mutation probability. Combining
both methods allows researchers to identify highly probable
mutations before querying predicted pathogenicity.
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To further develop this concept, we firstly annotated variants
with MRF likelihood scores and pathogenic prediction PHRED-
scaled CADD scores (Fig. 7) and secondly performed a manual
investigationof theclinical relevanceof topcandidates (TableE2).
WeusedHGMDasanunbiasedsourceofknownRAGdeficiency
cases in both instances. CADD score was very successful at
predicting the pathogenicity of a variant, (a high-density cluster
of variantswithCADDscores> 25) as shown in red in Fig. 7a.At
about the same rate, CADD score also predicted variants as path-
ogenic that are, to date, unreported (as pink in Fig. 7a). Indeed,
those unreported variantsmayverywell be pathogenic.However,
the likelihood of eachmutation varies.As such,we developed the
MRF score to account for that likelihood. As expected, the likeli-
hoodofmutationsoccurring thatwereunreportedwas lowaccord-
ing to MRF (Fig. 7b, pink), while the mutations which did occur
were highly enriched in at high MRF scores (Fig. 7b, red high-
density cluster > 0.043). Combining mutation prediction (MRF)
with pathogenicity prediction (tools like CADD) increases the
accuracy of pre-emptively targeting clinically relevant variants.
Figure 7c shows that while the number of variants presented to
date is relatively small, they already account for 36% of the top
MRF score candidates.
Discussion
Determining disease-causing variants for functional analysis
typically aims to target conserved gene regions. OnGnomAD,
56% of RAG1 (approx. 246,000 alleles) is conserved with no
reported variants. Functional validation of unknown variants
in genes with this level purifying selection is generally infea-
sible. Furthermore, we saw that a vast number of candidates
are “predicted pathogenic” by commonly used pathogenicity
tools, which may indeed be damaging but unlikely to occur.
To overcome the challenge of manual selection, we quantified
the likelihood of mutation for each candidate variant.
Targeting clearly defined regions with high MRF scores
allows for functional validation studies tailored to the most
clinically relevant protein regions. An example of high MRF
score clustering occurred in the RAG1 catalytic RNase H
(RNH) domain at p.Ser638-Leu658 which is also considered
a conserved Transib motif.
While many hypothetical variants with lowMRF scores may
be uncovered as functionally damaging, our findings suggest that
human genomic studies will benefit by first targeting variants
with the highest probability of occurrence (gene regions with
high MRF). Table E1 lists the values for calculated MRFs for
RAG1 and RAG2.
WehavepresentedabasicapplicationofMRFscoringforRAG
deficiency. Themethod can be applied to genomewide. This can
includephenotypicallyderivedweightstotargetcandidategenesor
tissue-specificepigeneticfeatures.Inthestatepresentedhere,MRF
scores areused for pre-clinical studies.Amore advanceddevelop-
ment may allow for use in single cases. During clinical investiga-
tions using personalized analysis of patient data, further scoring
methods may be applied based on disease features. A patient
Fig. 6 RAG1 PHRED-scaled
CADD score versus GnomAD
conservation rate and MRF score.
Allele frequency conservation
rate (top) is vastly important for
identifying critical structural and
functional protein regions. The
impact of mutation in one of these
conserved regions is often esti-
mated using CADD scoring
(middle). CADD score heatmap is
aligned by codon and separated
into three layers for individual
nucleotide positions. The MRF
score (bottom) (visualized using
the 75th percentile with 1% aver-
aging) highlights protein regions
that are most likely to present
clinically and may require pre-
emptive functional investigation
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phenotype can contribute aweight basedonknowngenotype cor-
relations separating primary immunodeficiencies or
autoinflammatory diseases [6]. For example, a patient with
autoinflammatoryfeaturesmayrequireaselectionthatfavorsgenes
associated with proinflammatory diseases such as MEFVand
TNFAIP3, whereas a patient withmainly immunodeficiencymay
havepreferentialscoringforgenessuchasBTKandDOCK8.Inthis
way, a check-list of most likely candidates can be confirmed or
excludedbywholegenomeorpanelsequencing.However,valida-
tionof these expanded implementations requires adeeper consoli-
dationof functional studies than iscurrentlyavailable.
Havrilla et al. [61] have recently developed a method with
similar possible applications for human health mapping
constrained coding regions. Their study employed a method that
included weighting by sequencing depth. Similarly, genome-
wide scoring may benefit from mutation significance cutoff,
which is applied for tools such as CADD, PolyPhen-2, and
SIFT [62]. We have not included an adjustment method as our
analysis was gene-specific but implementation is advised when
calculating genome-wide MRF scores.
TheMRFscorewasdevelopedtoidentifythetopmostprobable
variantsthathavethepotentialtocausedisease.Itisnotapredictorof
pathogenicity. However, MRF may contribute to disease predic-
tion; a clinicianmay ask for the likelihood of RAGdeficiency (or
any other Mendelian disease of interest) prior to examination
(Supplemental)[68].
Predicting the likelihood of discovering novel mutations has
implications in genome-wide association studies (GWAS).
Variants with low minor allele frequencies have a low discovery
rate and low probability of disease association [63], an important
consideration for rare diseases such as RAG deficiency. An anal-
ysis of the NHGRI-EBI catalogue data highlighted diseases
whose average risk allele frequency was low [63].
Autoimmune diseases had risk allele frequencies considered
low at approximately 0.4. Without a method to rank most prob-
able novel disease-causing variants, it is unlikely that GWASwill
identify very rare disease alleles (with frequencies < 0.001). It is
conceivable that a number of rare immune diseases are attribut-
able to polygenic rare variants. However, evidence for low-
frequency polygenic compounding mutations will not be avail-
able until large, accessible genetics databases are available, ex-
emplified by the NIHR BioResource Rare Diseases study [16].
An Interesting consideration when predicting probabilities of
variant frequency is that of protective mutations. Disease risk
variants are quelled at low frequency by negative selection, while
protective variants may drift at higher allele frequencies [64].
The cost-effectiveness of genomic diagnostic tests is al-
ready outperforming traditional, targeted sequencing [1].
Even with substantial increases in data sharing capabilities
and adoption of clinical genomics, rare diseases due to vari-
ants of unknown significance and low allele frequencies will
remain non-actionable until reliable predictive genomics
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Fig. 7 RAG1 PHRED-scaled
CADD score versus MRF score
against HGMD data. a A high
CADD score is a predictor of
deleteriousness. Both reported
(red) and non-reported residues
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CADD score. bMRF scores only
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high-likelihood variants, reflected
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for known RAG deficiency vari-
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between groups. AUC overlap
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74.28% (above intersects > 22.84
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tively). c The number of residues
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disease reported on HGMD ac-
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practices are developed. Bioinformatics as a whole has made
staggering advances in the field of genetics [65]. Challenges
that remain unsolved, hindering the benefit of national or
global genomics databases, include DNA data storage and
random access retrieval [66], data privacy management [67],
and predictive genomics analysis methods. Variant filtration in
rare disease is based on reference allele frequency, yet the
result is not clinically actionable in many cases.
Development of predictive genomics tools may provide a crit-
ical role for single-patient studies and timely diagnosis [23].
Conclusion
We provide a list of amino acid residues for RAG1 and RAG2
that have not been reported to date but are most likely to
present clinically as RAG deficiency. This method may be
applied to other diseases with hopes of improving prepared-
ness for clinical diagnosis.
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